Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Dasatinib Plus Protracted Temozolomide in Recurrent Malignant Glioma

NCT00734864 is registered in ClinicalTrials.gov with Annick Desjardins as lead sponsor.

NCT NCT00734864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00734864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Dasatinib Plus Protracted Temozolomide in Recurrent Malignant Glioma
Lead sponsor
Annick Desjardins
Phase
Phase 1
Overall status
Withdrawn
Start date
June 30, 2009
Completion date
June 30, 2012
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, anaplastic oligodendroglioma, glioblastoma multiforme, glioma, gliosarcoma